May 5-8







Taylor & Francis Online



Log in



Q

Home ▶ All Journals ▶ Expert Review of Anticancer Therapy ▶ List of Issues ▶ Volume 15, Issue 5 Onartuzumab in lung cancer: the fall of

Expert Review of Anticancer Therapy >

Volume 15, 2015 - Issue 5



Free access

3,199 30

Views CrossRef citations to date Altmetric

Listen

Editorial


Onartuzumab in lung cancer: the fall of Icarus?

Christian Rolfo M, Nele Van Der Steen, Patrick Pauwels & Federico Cappuzzo

Pages 487-489 | Published online: 30 Mar 2015

66 Cite this article

A https://doi.org/10.1586/14737140.2015.1031219



Full Article

Figures & data

References

66 Citations

Metrics

℮ Reprints & Permissions

P View PDF

Abstract

The development of targeted therapies has led to a revolution in non-small-cell lung cancer, and opened up possibilities for improved personalized medicine. With the

constant reliable

more fle

the ne com

versus e

points a

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our Privacy Policy

wever, Accept All to become approval for **Essential Only** al that erlotinib Settings uss several

Q Keywor

During the last decade, there has been a revolution in non-small-cell lung cancer (NSCLC) with the development of targeted therapies. The best known example being the inhibition of EGFR-activating mutations by tyrosine kinase inhibitors (TKIs), for example, erlotinib or gefitinib. Unfortunately, after a few months, these patients show signs of resistance. One of the resistance mechanisms against EGFR-TKIs is c-MET amplification, which occurs in approximately 10-20% of patients with acquired resistance [1,2].

Despite its fame as a resistance mechanism, the receptor also plays a role in TKI-naïve patients. In this population, c-MET overexpression can be found in 14-69% of patients [3] and de novo c-MET amplification in about 5% [4,5].

A number of targeted therapies against c-MET have been developed and several are in clinical trials. One of these inhibitors is the c-MET monovalent antibody onartuzumab of Genentech, which has received a lot of attention lately due to the failed Phase III trial in late-stage NSCLC in combination with erlotinib. Although the overall results of the randomized Phase II trial of onartuzumab in combination with erlotinib in advanced NSCLC were negative, analysis showed that the subgroup of c-MET immunohistochemistry (IHC)-positive patients showed both improved progression-free survival (1.5 vs 2.9 months; p = 0.04) and overall survival (7.4 vs 8.9 months; p =0.002) [6]. On the basis of these results, a randomized Phase III trial was initiated in c-MET IHC-positive patients [7], which was stopped prematurely due to the lack of clinically meaningful efficacy.

What arguments can explain the failure of this Phase III trial?

First, the -MET About Cookies On This Site positive Accept All We and our partners use cookies to enhance your website formalin IFIRM antiexperience, learn how our site is used, offer personalised Essential Onlmab [8,9]. total ME features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate This 84 on the web or interact with us across devices. You can Settings choose to accept all of these cookies or only essential equivo cookies. To learn more or manage your preferences, click resectio been tested. "Settings". For further information about the data we collect from you, please see our Privacy Policy which sh ng of the IHC

was in accordance with the mkina levels of c-MET. In terms of fixation, the pathologist

can be guided by the internal controls of the tissue (endothelium = 1+ staining intensity, bronchial epithelium = 2+ intensity), but the use of semi-quantitative controls is recommended [8]. About 50% of the screened patients could be enrolled in the trial. However, the scoring criteria can greatly influence the number of selected patients. As reported, the choice of biomarker was made based on a comparison between FISH and IHC in the Phase II study (on a small number of 66 patients). It should be noted that, as for IHC, the cutoff value for FISH can make a big difference. In the Phase II study, a MET/CEP7 ratio of 2 or a total copy number of 5 was used as a cutoff, whereas other studies (e.g., crizotinib in c-MET-amplified NSCLC) showed the best response in patients with a ratio of 5 or more. Should we focus more on HGF, the ligand of c-MET? As HGF is produced by the tumor microenvironment or can even be produced by the tumor cells themselves, it can also evoke the activation of c-MET and even resistance against gefitinib [10,11]. The great number of selected patients might have obscured beneficial results in the actual group of patients that could benefit from treatment with onartuzumab.

The second comment that can be made is the fact that the c-MET status is determined on archival tissue of patients treated with one or two lines of chemotherapy. As resection/biopsy is done at the time of initial diagnosis, the level of c-MET expression may change during treatment, as has been reported for radiotherapy [12], raising the question if archival formalin-fixed paraffin-embedded material is a good estimate for the level of c-MET expression after one or more lines of treatment. Another problem that arises with the use of archival tissue is that the quality of the tissue will vary between different sites, due to differences in fixation time and procedure. Since fixation can have a big effect on the performance of an IHC assay, this again might influence the results.

Third, given the known success of erlotinib in EGFR-mutated patients, it is remarkable

that only presente variation evider with MET and MET can (TGF-B a

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our Privacy Policy

Accept All

ne results

ne results

ne results

ne results

preclinical

in patients

that the c
wed that c
scription

y activates

c-MET, but that c-MET needs the HER3 receptor to activate EGFR [16]. There is no

doubt that there exists a connection between both pathways, the only question is if EGFR is as strongly activated by c-MET as c-MET is activated by EGFR. In fact, the dual inhibition of c-MET and EGFR might have no real impact. Nevertheless, the results seen in the Phase II trial might be biased since the c-MET-positive arm contained a higher population of EGFR-mutant NSCLC patients in the erlotinib + onartuzumab arm (20%) in comparison with 7% EGFR-mutant patients in the erlotinib + placebo arm. This would mean that the real potential target population should present with both an EGFR mutation and c-MET positivity. At the American Society of Clinical Oncology 2014, data from the Phase III trial were presented but submolecular analysis was still ongoing.

Although this clinical trial may have failed, it gives rise to a lot of new questions and encourages the discussion of which c-MET biomarker to use for optimal patient selection. Should we really quit choosing c-MET IHC as a biomarker? Or do we need to change the IHC cutoffs? Is it ethical to include a large number of patients in a Phase III study (490 patients) when we have evidence of lack of efficacy in the Phase II study? Must we be more cautious with the design of clinical studies? In oncology, history continues to demonstrate that matching the right patient (with the appropriate biomarker) with the appropriate drug is the winning team [13]. Maybe we should, like Icarus, fly low to avoid falling down and try to reach our destination.

Financial & competing interests disclosure


The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.


No writin

About Cookies On This Site

Refer

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our Privacy Policy








PubMed | Web of Science ® | Google Scholar

.2. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011;103:645-61



	t. Proc Natl Acad Sc	et al. Signaling networks as i USA 2008;105:692-7 Science ® Google Scholar	sembled by oncogenic EGFR
kinases t			
Download PD			X (7) in M
	research (1) ople also read	Recommended articles	Cited by 30
Autophagy	onsky et al. line: 8 Feb 2021		
Yue Shen et	t al.	ckpoint drugs for non-small cell lung	g cancer >
Guideli	About Cookies On This Site		
Dar	We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our Privacy Policy		

Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

Keep up to date

Register to receive personalised research and resources by email



Sign me up











Copyright © 2024 Informa UK Limited Privacy policy Cookies Terms & conditions



Registered in England & Wales No. 3099067

5 Howick Place | London | SW1P 1WG

About Cookies On This Site



We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our Privacy Policy



Essential Onl

Settings